Opioid Dependency with Methadone Intervention

24
BY: AMBER MEDLIN, KERRY GOLDMAN, MADISON GOLDMAN, AND KAMI PEREZ OPIOID DEPENDENCY AND METHADONE INTERVENTION

description

Opioid Dependency and Methadone Intervention, Research Poster

Transcript of Opioid Dependency with Methadone Intervention

  • 1. B Y : A M B E R M E D L I N , K E R R Y G O L D M A N , M A D I S O N G O L D M A N , A N D K A M I P E R E Z OPIOID DEPENDENCY AND METHADONE INTERVENTION

2. INTRODUCTION The purpose of the study What will be analyzed The research 3. REVIEW OF LITERATURE Opioid Dependency Risks and Causes Interventions and Treatments Group/Individual Therapy Medication Management Therapy (focus on Methadone) The Need for Future Research 4. OPIOID DEPENDENCY What is an Opiate? Examples of Opiates DSMV 5. OPIOID DEPENDENCY CONT. Risks Statistics The Psychological Effects Effects on Children 6. OPIOID DEPENDENCY CONT. What Causes Opiate Dependency? Life Stressors 7. INTERVENTIONS AND TREATMENTS Group/Individual Therapy Pros Cons Medication Management Therapy (Methadone) History How is it Used? 8. FUTURE RESEARCH NEEDS Availability Abstinence 9. IDENTIFICATION AND MEASUREMENT OF VARIABLES 10. VARIABLES Dependent= length of abstinence Independent= Medication Maintenance Treatment (MMT) 11. MEASURING TOOLS Likert scale based of the criteria from the American Society of Addiction Medication (ASAM) Urine Analysis (UA) give once a month randomly. The UA will measure Opioid and other illicit substances. 12. ASAM CRITERIA The ASAM is used in assessing Patient placement criteria (PPC). The ASAM criteria is a guideline used by professionals in assessing the appropriate level of care for individuals with a diagnosis of addiction. ASAM is also used in monitoring and measuring the progress of the individuals treatment. 13. ASAM SIX DIMENSIONS 1: Acute Intoxication and/or Withdrawal 2: Biomedical Conditions and Complications 3:Emotional/Behavioral or Cognitive Conditions and Complications 4: Readiness to Change 5: Relapse/Continued Use or Continued Problem Potential 6: Recovery/Living Environment 14. SURVEY The survey was made up from a questionnaire equaling 18 questions. 3 questions relating to each ASAM dimension. The Likert Scale: 1= always, 2= most of the time, 3= some of the time 4=very rarely 5= never 15. SAMPLING PLAN STUDY DESIGN DATA COLLECTION METHODS 16. PLAN FOR SAMPLING 200 Subjects (N=200) Current clients of MAKK Treatment Center Inclusion Criteria: Age 21 and older Diagnosed with Opiate Dependency Disorder Met the criteria for entrance into the program Pregnancy testing for female subjects Absent of serious psychological and medical disorders Written informed consent 17. STUDY DESIGN AND DATA COLLECTION METHODS Study Design A single-site, randomized, longitudinal design Is utilized for this study lasting for a period of 7 years. 18. DATA COLLECTION METHOD MAKK Treatment Center (600 clients) Licensed to dispense Methadone and perform MMT Subjects randomly assigned to study Data collection 19. COLLECTION TIMES & METHODS Collection times Entry to the study Completion of the intervention (12 months) Completion of the Methadone tapering (6 months) Monthly during abstinence phase (5 years-6 months) 20. COLLECTION METHODS Counselor AdministeredCustomized Survey Based on ASAM Urinalysis Testing 21. DATA ANALYSIS 22. DATA ANALYSIS Opioid dependency has been managed by medication maintenance treatment for which methadone has been effective in maintaining abstinence. 23. THE STUDY Research was based on a longitudinal analysis. 200 Participants The aim of study was to observe how effective methadone was in obtaining abstinence. Measurements: monthly random urinalysis and ASAM questionnaire. Data that was not included: gender and race. 24. ANTICIPATED RESULTS The researchers will hope to see a decrease in opioid and other substance use throughout the duration of the treatment of MMT and then abstinence of all substances for the length of time studied after the medication is removed. Limitations and predicted concerns were drop in retention rate and high percentage of urine drug screen refusals.